Sklaroff R B, Casper E S, Magill G B, Young C W
Cancer Treat Rep. 1980;64(12):1247-51.
We conducted a phase I study of 6-diazo-5-oxo-L-norleucine given iv on a twice weekly schedule. Twenty-six evaluable patients received 31 courses of the drug. Doses ranged from 100 to 500 mg/m2. Nausea with vomiting was the dose-limiting toxic effect, transient thrombocytopenia was seen frequently, and mucositis occurred in 39% of the patients. No definite therapeutic responses were observed in 18 patients with measurable lesions. The recommended dose for phase II studies is 200-300 mg/m2 iv twice weekly.
我们进行了一项关于6-重氮-5-氧代-L-正亮氨酸的I期研究，该药物通过静脉注射给药，每周两次。26名可评估患者接受了31个疗程的该药物治疗。剂量范围为100至500mg/m²。恶心伴呕吐是剂量限制性毒性反应，经常出现短暂性血小板减少，39%的患者发生了粘膜炎。18名有可测量病灶的患者未观察到明确的治疗反应。II期研究的推荐剂量为200 - 300mg/m²静脉注射，每周两次。
